-
Sector Analysis
NewMultiple Myeloma Epidemiology Analysis and Forecast to 2032
Multiple Myeloma Vaccines Report Overview In the 8MM, there were 80,305 diagnosed incident cases of multiple myeloma vaccines in 2022. The diagnosed incident cases of multiple myeloma vaccines are expected to register an AGR of more than 1% during 2022-2032. Multiple myeloma (MM) is a hematologic cancer that forms in a type of white blood cell called plasma cells. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but MM causes cancer cells to accumulate...
-
Product Insights
NewAcute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Clinical Trials Overview The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial report consists of 3259 trials. The report provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trial scenario. The report provides top-line data relating to the clinical trials on Acute Lymphocytic Leukemia. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of...
-
Sector Analysis
Acute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Acute Myeloid Leukemia (AML) Market Report Overview The acute myeloid leukemia (AML) market in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China) was $2.3 billion in 2022. Steady growth is anticipated at a CAGR of more than 4% throughout the forecast period as the number of AML patients continues to climb and new therapies arrive in the 8MM. The AML market research report offers an overview of AML, including epidemiology, symptoms, diagnosis,...
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Sector Analysis
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Product Insights
Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Multiple Myeloma Clinical Trial Market Overview The Multiple Myeloma (Kahler Disease) clinical trial market research report provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Diffuse Large B-Cell Lymphoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Diffuse Large B-Cell Lymphoma Clinical Trials Market Report Overview The Diffuse Large B-Cell Lymphoma clinical trial market research report provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Sector Analysis
Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Myelofibrosis Market Report Overview The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). Incyte was the first company to capitalize on the clinical and commercial potential of the MF market with the landmark approval of...
-
Product Insights
Acute Myelocytic Leukemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
AML Clinical Trials Market Report Overview The AML clinical trial market research report provides an overview of AML clinical trials scenario. The report provides top-line data relating to the clinical trials on AML. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
Post-Polycythemia Vera Myelofibrosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Post-Polycythemia Vera Myelofibrosis Clinical Trials Market Report Overview The post-polycythemia vera myelofibrosis (PPV-MF) clinical trial market research report provides an overview of PPV-MF clinical trials scenario. The report provides top-line data relating to the clinical trials on PPV-MF. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
B-Cell Non-Hodgkin Lymphoma (NHL) Marketed and Pipeline Drugs Market Report Overview B-cell NHL generally arises in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to involve distant sites such as the lung or brain in the later stages of the disease. NHLs are further categorized into indolent or aggressive prognostic subtypes, which further influence outcomes and treatment decisions. The B-Cell NHL marketed and pipeline drugs market research report includes an assessment of...
-
Product Insights
Mycosis Fungoides Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Mycosis Fungoides Clinical Trials Market Report Overview The Mycosis Fungoides clinical trial market research report provides an overview of the Mycosis Fungoides clinical trials scenario. The report provides top-line data relating to the clinical trials on Mycosis Fungoides. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Sector Analysis
Chronic Lymphocytic Leukemia (CLL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market value for the 15 markets (15M) was $13.2 billion in 2021. This included both cell therapies and established/traditional CLL therapies. The 15 markets comprise the 8 major markets and seven countries known to have increased potential for cell therapies given the current drug development landscape, namely Australia, South Korea, Belgium, Denmark, Switzerland, Israel, and Canada. The CLL market research report provides an analysis of the key dynamics...
-
Sector Analysis
Acute Lymphocytic Leukemia (ALL) – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Accessing in-depth insights from the ‘Acute Lymphocytic Leukemia Cell Therapy Market’ report will help you: Assess the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) and identify the potential countries for growth opportunities within the ALL-cell therapy market. Analyze the clinical and commercial landscapes of each indication, with pricing assumptions Evaluate indication-specific unmet needs and competitive assessments by Class of Therapy Identify the Likelihood of Approval Analysis...
-
Sector Analysis
Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031
Explore in-depth market insights from the following data in our ‘Multiple Myeloma Cell Therapy Market’ report: Access updated epidemiology for patient populations relevant to cell therapy in 2021-2031 Review updated prescription habits at the class level for already established therapies (defined in our analysis as chemotherapy, targeted therapies, and others [such as immune checkpoint inhibitors or hormone therapies]) and compare their future projections to cell therapy pipeline drugs Full market assessment in the 8MM of all currently marketed and late-stage pipeline cell therapy drugs with drug-level forecasts, supplemented by class-level forecasts for early-stage molecules Explore indication-specific top-line sales forecasts across 15 countries, in the 8MM and...
-
Sector Analysis
B-Cell Non-Hodgkins Lymphoma Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2021-2031
Access and explore the following in-depth insights from the ‘B-Cell Non-Hodgkins Lymphoma Cell Therapy Market’ report: Disease epidemiology including - Patient segmentation, staging & progression rates, and Disease incidence/prevalence. Marketed products with a breakdown established versus cell therapies, backed with primary research validated base year forecast Commercial assessment and Forecast by number of patients treated per class and future sales projection based on competitive assessment Launch date assessment with estimated launch dates by class of cell therapy and indication-specific assumptions. Evaluation...
-
Sector Analysis
Acute Myeloid Leukemia Cell Therapy Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs and Forecast, 2031
Acute Myeloid Leukemia Market Report Overview The AML market value for the 15 markets (15M) was $3.1 billion in 2021. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a malignancy of the hematopoietic system caused by the abnormal proliferation or differentiation of myeloid progenitors in the bone marrow and peripheral blood. AML is relatively rare and has a poor prognosis, particularly in elderly patients. The first approval for cell therapy drugs is anticipated in 2023, which is expected to positively...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.